AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02181478 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: umbilical cord blood transplantation
Description: Following RIC, on day T+0, dimethylsulphoxide will be removed from the cord blood cells and given as transplant.
Study NCT02181478 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cell transplantation
Description: The total dosage of hMSC will be 2x10\^6cells/kg (+/-20%).
Study NCT03132103 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Vitamin D3
Study NCT03132103 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Vitamin D3
Study NCT03132103 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Solar simulated radiation (SSR)
Study NCT03132103 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SSR
Study NCT01497509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bolus 10mL 0.25% bupivacaine/ep 1:600,000; infusion 10mL/hour 0.25% bupivacaine and epi 1:800,000
Study NCT01497509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bolus 10mL 0.25% bupivacaine/ epinephrine 1:600,000;infusion 10mL/hour 0.25% bupivacaine, 2 mcg/mL fentanyl, and epinephrine 1:800,000
Study NCT01497509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bolus 10mL 0.25% bupivacaine, 10mcg/mL fentanyl, and epi 1:600,000; infusion 10mL/hour 0.25% bupivacaine, 2.5 mcg/mL fentanyl, and epi 1:800,000
Study NCT01497509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bolus 10mL 0.25% bupivacaine, 5 mcg/mL fentanyl, and epi 1:600,000; infusion 10mL/hour 0.25% bupivacaine, 3.5 mcg/mL fentanyl, and epi 1:800,000
Study NCT01059786 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) Saline
Description: Additional treatment with intravenous (IV) saline may be indicated.
Study NCT03274427 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Basic drugs therapy of HCC by TACE
Description: Basic drugs include: 1. Molecular targeted drugs for HCC：apatinib; 2. Antiviral drugs (ETV or TDF) should be given to patients who were infected with HBV or HCV; 3. Patients with liver dysfunction should be treated with conventional hepatoprotective agents drugs (including glycyrrhizin, reduced glutathione, vitamin C，etc); 4. Patients with ascites symptoms should be treated with furosemide and spironolactone according to the urine volume, and they also should be treated with proton pump inhibitors in the prevention of gastrointestinal bleeding; 5. Other basic diseases were treated routinely.
Study NCT01059786 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous (IV) Saline
Description: Additional treatment with intravenous (IV) saline may be indicated.
Study NCT03010254 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACRYSOF® IQ Extended Depth of Focus IOL
Description: Implantable IOL intending to extend the depth of focus and provide continuous functional vision from distance to near while maintaining distance vision and a visual disturbance profile comparable to a monofocal IOL; intended for long-term use over the lifetime of the pseudophakic subject
Study NCT03010254 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ACRYSOF® IQ Monofocal IOL
Description: Monofocal IOL implanted for long-term use over the lifetime of the pseudophakic subject
Study NCT03010254 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Description: IOL bilateral implantation
Study NCT03010254 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract surgery
Description: IOL bilateral implantation
Study NCT03274427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arginine hydrochloride
Description: Arginine hydrochloride injection 5g/dose; 40g/d; ivgtt; sustained medication for 24 days; drug withdrawal for 4 days.
Study NCT03274427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimetazidine hydrochloride
Description: Trimetazidine hydrochloride, 20mg/tablet, 40mg, twice a day.
Study NCT03614416 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EOXY device
Description: Sp02 and HR measures from EOXY device are simulateously compared to gold standard measures : Sa02 sampling measures and pulse oximeter gold standard
Study NCT03614416 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gold standard oximeter
Description: Sp02 and HR measures from EOXY device are simulateously compared to gold standard measures : Sa02 sampling measures and pulse oximeter gold standard
Study NCT03614416 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SaO2 sampling
Description: Sp02 and HR measures from EOXY device are simulateously compared to gold standard measures : Sa02 sampling measures and pulse oximeter gold standard
Study NCT01081301 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Living with Hope Program
Description: The LWHP consists of the LWH film featuring caregivers of patients with advanced cancer describing their hope and a hope activity Stories of the Present. Following viewing of the video with trained research assistants (RAs), (without discussion) the RA's will instruct the subjects to take 5 minutes at the end of the day and write about their thoughts, challenges and what gave them hope over a 2 week time period. Subjects can choose to use a journal, a computer or audiotape their journals.
Study NCT04413903 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The Effect of Different Mechanical Ventilator Modes on Optic Nerve Diameter and Cognitive Functions in Laporoscopic Cholecystectomy Operations
Description: The Effect of Different Mechanical Ventilator Modes on Optic Nerve Diameter and Cognitive Functions in Laporoscopic Cholecystectomy Operations
Study NCT03184987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI 100/62.5/25 mcg
Description: Subjects will self-administer the study treatment via the ELLIPTA device. The ELLIPTA holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister. ELLIPTA is a registered trademark of GSK groups of companies.
Study NCT03184987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI 200/62.5/25 mcg
Description: Subjects will self-administer the study treatment via the ELLIPTA device. The ELLIPTA holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister. ELLIPTA is a registered trademark of GSK groups of companies.
Study NCT03184987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: Salbutamol is a rescue medication administered via metered-dose inhaler (MDI) which will be used when needed during the study.
Study NCT03008902 — intervention group
Intervention type: PROCEDURE
Intervention: Near-infrared passive motion capture recording
Description: Full body movement will be recorded during movements using near infrared passive motion capture. This procedure is non-invasive and standard practice in biomechanics labs. Movement will be recorded using an eight-camera system. Retroreflective markers are placed at strategic joint locations to characterize limb movement. Accuracies of the marker positions are sub-millimeter, and allow accurate characterization of limb rotation and translation during movements. Passive reflective marker clusters (3 markers each) will be attached to subjects at 8 locations along the spine. Additional markers will be applied to the manubrium of the sternum, head, pelvis, and extremities. Eight EMG surface electrode pairs will be used to record activation from the left and right erector spinae, latissimus dorsi, trapezius and rectus abdominis muscles during all motions.
Study NCT02905617 — intervention group
Intervention type: DEVICE
Intervention: Sientra 207 Silicone Gel Breast Implant
Description: The Sientra 207 Silicone Gel Breast Implant is a textured, round device with high-strength cohesive plus (HSC+) silicone gel fill.
Study NCT03523273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Initiate at 0.6mg S.C. daily for 1 week; subjects will return to the Clinical Research Unit (CRU) each week until an increase by 0.6mg/day in weekly intervals to a dose of 3.0 mg/day is achieved (\~4 weeks). Once maintenance dose of 3.0 mg is achieved, subjects will return approximately every 4 weeks to obtain new supply of study medication.
Study NCT03523273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administration will match the study drug.
Study NCT02157441 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lower uterine compression sutures
Description: intervention is lower uterine compression sutures (involved bilateral uterine artery ligation and compression of the lower uterine segment at the same time with one circular stitch) as a conservative treatment for the treatment of postpartum hemorrhage in women with placenta previa complete centralis.
Study NCT00273754 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: Children in group one will receive caffeine benzoate 20 mg/kg i.v., which is equal to a 10 mg/kg caffeine base.
Study NCT00273754 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Children in group two will receive an amount of normal saline equal to Caffeine
Study NCT03081676 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride 1Mg Tablet
Description: Glimepiride
Study NCT03081676 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon-like Peptide-1
Description: GLP-1 infusion
Study NCT03081676 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucose-Dependent Insulinotropic Polypeptide
Description: GIP-infusion
Study NCT03081676 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo
Study NCT03081676 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo
Study NCT03081676 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo infusion
Description: Placebo (saline)
Study NCT03081676 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo infusion
Description: Placebo (saline)
Study NCT02963987 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food and Beverage Portion Size
Description: Variations of Food and Beverage Portion Size (100% Baseline portions and increased 50% for 150% portions)
Study NCT02180633 — intervention group
Intervention type: OTHER
Intervention: Optical Coherence Tomography Scan
Description: As an observational study, the only interventive action taken is the acquisition of a non-invasive volumetric image of the retina via optical coherence tomography (OCT).
Study NCT01765426 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDV
Description: TDV suspension for intradermal administration
Study NCT01765426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Phosphate buffered saline (PBS)
Study NCT00888251 — intervention group
Intervention type: OTHER
Intervention: Comprehensive weight management program
Description: Full meal replacement, behaviorial modification, medical monitoring, exercise.
Study NCT03240796 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: minimal invasive surgery and secondary IOL implantation
Description: We decreased the size of the capsulorhexis opening to 1.0-1.5 mm in diameter and moved the location of the capsulorhexis to the peripheral area of the lens instead of the central area. A 0.9 mm phacoemulsification probe was used to remove the lens contents and/or cortical opacities. Secondary IOL implantation: implant the IOL either into the capsule bag or fix at the ciliary sulcus.
Study NCT03240796 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: traditional cataract surgery and secondary IOL implantation
Description: traditional cataract surgery: anterior continuous capsulorhexis + irrigation/aspiration + posterior capsulorhexis + anterior vitrectomy (ACCC+ I/A + PCCC + Anti-vit).~Secondary IOL implantation: implant the IOL either into the capsule bag or fix at the ciliary sulcus.
Study NCT03184987 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACQ-7
Description: ACQ-7 will be used for the assessment of control status of asthma.
Study NCT02605811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Study NCT02605811 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: prophylaxis cranial radiotherapy
Description: 2
Study NCT00969176 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: paracetamol
Description: Intravenous paracetamol administration in neonates, loading dose 20 mg/kg, followed by a Gestational age-dependent maintenance dose of 10-20 mg/kg/24 h, divided in 4 doses (each 6h)
Study NCT03451344 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated rehabilitation group
Description: Participant in integrated rehabilitation group needs to visit their corresponding social worker and accept illicit drug test every two months. Social worker will help their corresponding client to apply for social benefits accordingly, and provide counseling irregularly if necessary. The integrated rehabilitation group received the standardized community-based rehabilitation described above and simultaneously received a 6-month integrated rehabilitation based on CAREs (Community-based Addiction Rehabilitation Electronic System).CAREs was developed by the department of addiction research in Shanghai Mental Health Center(SMHC), with functions including education, support, psychological intervention and other functions.
Study NCT00852124 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: VSL#3 or placebo
Description: 1 packet 2 x daily of placebo
Study NCT01904760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine(4㎍/mL) : 0.5㎍/kg/hr infusion for 1 hour before operation is completed and 0.2-0.7㎍/kg/hr infusion continuously until 6:00am the next day.
Study NCT01904760 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: Normal saline 0.9% (guess as 4㎍/mL) : 0.5㎍/kg/hr infusion for 1 hour before operation is completed and 0.2-0.7㎍/kg/hr infusion continuously until 6:00am the next day
Study NCT03480620 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online Telerehabilitation Platform Access
Description: Participants will have 24/7 access to a standardized set post-discharge exercise videos and self-management instructions across multiple internet connected devices (e.g. computer, tablet, smartphone). Standardized exercises include a flexibility routine that participants learned and performed with a physical therapist while in the pain management program. Self-management instructions are also written versions of concepts learned and practiced with a member of the multidisciplinary team during the pain management program.
Study NCT03480620 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Participants are given a DVD of the standardized post-discharge exercise videos and a written copy of the self-management instructions as described in the experimental group.
Study NCT00324727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given throug isolated hepatic artery infusion
Study NCT00324727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: regional chemotherapy
Description: Patients receive the best alternative therapy
Study NCT00324727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: systemic chemotherapy
Description: Patients receive the best alternative therapy
Study NCT00324727 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hepatic artery embolization
Description: Patients receive the best alternative therapy
Study NCT04351633 — intervention group
Intervention type: OTHER
Intervention: questionnaire assesment
Description: questionnaire assesment
Study NCT01026311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coenzyme q 10
Description: 200 mg of Coenzyme q 10
Study NCT01026311 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 placebo q d during treatment period
Study NCT01873183 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Goal directed fluid therapy
Study NCT01960049 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine + iv PCA
Study NCT01960049 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: saline and IV PCA
Study NCT01529710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myrrh
Description: Subjects will be treated by Mirazid as 600 mg oral (Soft Gelatin Capsules) for 6 consecutive days or 40mg/Kg body weight of Praziquantel as a single oral dose. Subjects will be evaluated for success of treatment at 12 weeks of treatment. Evaluation will be done by examining urine or stool samples for Schistosomiasis including egg counts for the positive cases.
Study NCT01529710 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Myrrh
Description: Subjects will be treated by Mirazid as 600 mg oral (Soft Gelatin Capsules) for 6 consecutive days or 40mg/Kg body weight of Praziquantel as a single oral dose. Subjects will be evaluated for success of treatment at 12 weeks of treatment. Evaluation will be done by examining urine or stool samples for Schistosomiasis including egg counts for the positive cases.
Study NCT01008189 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self- study comparison group
Description: Caregivers, children and adolescents each received three books about coping with grief following the death of a loved one plus a syllabus to guide reading
Study NCT01008189 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Bereavement Program
Description: 12 session groups for caregivers and bereaved children and adolescents plus two individual sessions
Study NCT02052011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: Subjects will take the extended-release Ranolazine for a total of 4 weeks. Subjects will take 500 mg twice daily for the first week and then 1000 mg twice daily for remaining period (Dosing will be adjusted with concomitant use of diltiazem, verapamil, erythromycin, simvastatin or metformin).
Study NCT02052011 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00750581 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin
Description: Infants randomized to Escalating Dose group will receive indomethacin (0.2 mg/kg/dose) at 12 hr intervals for 2 doses, followed by indomethacin (0.3 mg/kg/dose) at 12 hr interval for 2 doses, then Indomethacin (0.4 mg/kg/dose) at 12 hr interval for 2 doses, increased to indomethacin (0.5 mg/kg/dose) at 12 hour interval for 2 doses and finally indomethacin 0.6 mg/kg/dose at 12 hourly interval for 2 doses.
Study NCT00750581 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Indomethacin
Description: Infants randomized to Escalating Dose group will receive indomethacin (0.2 mg/kg/dose) at 12 hr intervals for 2 doses, followed by indomethacin (0.3 mg/kg/dose) at 12 hr interval for 2 doses, then Indomethacin (0.4 mg/kg/dose) at 12 hr interval for 2 doses, increased to indomethacin (0.5 mg/kg/dose) at 12 hour interval for 2 doses and finally indomethacin 0.6 mg/kg/dose at 12 hourly interval for 2 doses.
Study NCT01599585 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Description: Behavioral activation(BA)will be delivered in 8 weekly sessions via webcam for the in-home arm or face to face in the in-person arm. Behavioral activation attempts to help depressed individuals reengage in their lives through focused activation strategies.
Study NCT01599585 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Activation
Description: Behavioral activation(BA)will be delivered in 8 weekly sessions via webcam for the in-home arm or face to face in the in-person arm. Behavioral activation attempts to help depressed individuals reengage in their lives through focused activation strategies.
Study NCT00923806 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PG13-CEA_TCR (Anti-CEA TCR PBL)
Study NCT00923806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: 720,000 IU/kg intravenous over 15 minutes every 8 hours for up to 5 days
Study NCT02192190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2951742
Description: Administered subcutaneously (SC)
Study NCT02192190 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo- oral
Description: Administered orally
Study NCT02192190 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo- oral
Description: Administered orally
Study NCT02192190 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo - SC
Description: Administered SC
Study NCT00448383 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: 40mg every other week
Study NCT04302714 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hysteroscopic injection
Description: Hysteroscopic injection
Study NCT04302714 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical injection
Description: Cervical injection
Study NCT05388513 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical Resection
Description: Surgically treated patients included